Business Context and Reporting Period
Company: Torchmark Corporation (Note: Input metadata referenced "Globe Life Inc.", but the filing text identifies the registrant as Torchmark Corporation).
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: Torchmark is an insurance company marketing individual life and supplemental health insurance products, primarily to middle-income Americans through niche distribution systems. The company also markets annuities and manages a significant investment portfolio to support policy liabilities.
Key Financial Metrics (Six Months Ended June 30, 2006)
| Metric | 2006 (YTD) | 2005 (YTD) |
|---|---|---|
| Total Revenue | $1,726.1 million | $1,587.8 million |
| Total Premiums | $1,408.5 million | $1,266.3 million |
| Net Investment Income | $308.3 million | $299.8 million |
| Net Income | $247.6 million | $250.2 million |
| Diluted EPS | $2.42 | $2.34 |
| Cash Flow from Operations | $432.2 million | $459.4 million |
| Total Assets | $14,782.5 million | $14,768.9 million (Dec 31, 2005) |
| Total Liabilities | $11,655.1 million | $11,336.1 million (Dec 31, 2005) |
| Shareholders' Equity | $3,127.4 million | $3,432.8 million (Dec 31, 2005) |
| Long-Term Debt | $591.8 million | $353.3 million (Dec 31, 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 8.7% year-over-year, driven by an 11.2% increase in total premiums. This growth was significantly influenced by the introduction of Medicare Part D business, which contributed $122.1 million in GAAP premiums.
- Net Income Decline: Despite revenue growth, net income decreased 1.0% to $247.6 million. This was primarily due to a reduction in realized investment gains (down from $7.6 million in 2005 to $1.5 million in 2006) and the adoption of SFAS 123R, which introduced $3.5 million in stock-based compensation expense.
- Segment Performance:
- Life Insurance: Premiums grew 4% to $761.4 million. Underwriting income increased 6% to $198.0 million.
- Health Insurance: Excluding Part D, premiums declined 1%. However, including Part D, total health premiums rose 16%. Underwriting income for the health segment (including Part D) increased 11% to $99.9 million.
- Investment Segment: Excess investment income declined 3% to $158.5 million due to higher financing costs and increased interest credited on policy liabilities, offsetting a 3% rise in net investment income.
- Capital Structure: Long-term debt increased significantly due to the issuance of $250 million in Senior Notes and $123.7 million in Junior Subordinated Debentures in June 2006. Shareholders' equity decreased by approximately $305 million from the prior year-end, largely due to $283 million in share repurchases and $452 million in net unrealized losses on the investment portfolio.
Guidance, Outlook, and Risks
- Management Commentary: Management views the Medicare Part D business as having a full-year loss ratio of approximately 80%. They note that while GAAP reporting shows higher costs in the first half of the year, segment reporting defers these costs to match revenue more evenly. Management expects the 2006 after-tax stock option expense to be approximately $4 million.
- Investment Strategy: The company continues to invest in long-term, investment-grade fixed maturities. In Q2 2006, new money yields reached 6.98%, matching the portfolio average for the first time in three years. The company sold all remaining interest-rate swap agreements in Q2 2006 due to rising short-term rates.
- Share Repurchases: The company repurchased 5.0 million shares for $283 million during the six-month period. The Board reaffirmed the ongoing repurchase program with no specified limit, dependent on excess cash flow and market conditions.
- Risks and Contingencies:
- Legal Proceedings: Torchmark is involved in various litigation, including a securities class action regarding Vesta Insurance Group (trial set for October 2006) and class actions in Alabama and Mississippi involving punitive damages. Management does not currently believe these will have a material adverse effect.
- Interest Rate Risk: Fluctuations in interest rates impact the fair value of the investment portfolio and shareholders' equity. The company notes that SFAS 115 accounting rules create volatility in reported equity that does not reflect the economic reality of the matching assets and liabilities.
- Regulatory Risk: Changes in Medicare regulations or tax laws could impact the profitability of Medicare Supplement and Part D products.
Investor Verification Checklist
- Medicare Part D Impact: Verify the reconciliation between GAAP and segment reporting for Medicare Part D, specifically the $36 million deferral of benefits and the $30 million risk-sharing premium adjustment excluded from segment results.
- Investment Portfolio Valuation: Review the $219 million in gross unrealized losses on fixed maturities and the impact of SFAS 115 on reported shareholders' equity versus economic capital.
- Debt Issuance Costs: Confirm the amortization schedule and impact of the $8.3 million in issue expenses related to the new June 2006 debt offerings.
- Stock Option Expense: Monitor the impact of SFAS 123R adoption on future earnings, as the company anticipates $4 million in after-tax expense for the full year 2006.
- Legal Settlements: Track the status of the Vesta Insurance Group litigation and the potential for punitive damage awards in Alabama and Mississippi proceedings.